Lexaria Bioscience To Initiate New, Five-Week Human Clinical Study To Evaluate 2 Oral DehydraTECH-Semaglutide Compositions Against Wegovy

Lexaria Bioscience Corp. (NASDAQ: LEXX) has announced the initiation of a new five-week human clinical study, Human Pilot Study #7, to evaluate two oral DehydraTECH-semaglutide compositions against Wegovy tablets. The study will involve a parallel group design with three separate arms to assess safety, tolerability, and pharmacokinetic properties. Contracts with a contract research organization have been signed, and ethics approval submissions are underway.